Patents-Review.com
🔗 Permalink
Assignee profile:

CELLDEX THERAPEUTICS, INC.

City:

Needham, Massachusetts

Country:

United States

Published Applications:

19

Last publication date:

2016-06-30

Patent Grants:

15

Last grant date:

2017-05-16

Top Inventors for applications by CELLDEX THERAPEUTICS, INC.

These are the the leading inventors for applications assigned to CELLDEX THERAPEUTICS, INC.:

Recent patent applications by CELLDEX THERAPEUTICS, INC.

CELLDEX THERAPEUTICS, INC. based in Needham, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2016-06-30 ✅ Patent 9,649,357 granted on 2017-05-16
US20160184392A1
Human necessities

Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)

 #2 | 2016-01-26 ✅ Patent 9,243,064 granted on 2016-01-26
US10769144
Chemistry; metallurgy

Antibody vaccine conjugates and uses therefor

 #3 | 2013-08-08
US20130202527A1
Chemistry; metallurgy

Method of Treating Ovarian and Renal Cancer Using Antibodies Against T Cell Immunoglobulin Domain And Mucin Domain 1 (TIM-1) Antigen

 #4 | 2013-04-25 ✅ Patent 9,624,300 granted on 2017-04-18
US20130101593A1
Chemistry; metallurgy

Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)

 #5 | 2013-02-07
US20130034573A1
Human necessities

VACCINE COMPOSITIONS

 #6 | 2013-01-24 ✅ Patent 8,846,873 granted on 2014-09-30
US20130022597A1
Chemistry; metallurgy

Antibodies directed to GPNMB and uses thereof

 #7 | 2012-12-06 ✅ Patent 8,586,720 granted on 2013-11-19
US20120309031A1
Chemistry; metallurgy

Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)

 #8 | 2012-09-13 ✅ Patent 9,649,356 granted on 2017-05-16
US20120232020A1
Human necessities

Method of improving transplant function using soluble complement receptor type I (sCR1)

 #9 | 2012-08-23
US20120213771A1
Chemistry; metallurgy

ANTIBODIES THAT BIND HUMAN CD27 AND USES THEREOF

 #10 | 2012-06-14 ✅ Patent 9,095,626 granted on 2015-08-04
US20120148596A1
Chemistry; metallurgy

Monoclonal antibodies to dendritic cells

 #11 | 2012-03-22 ✅ Patent 9,295,713 granted on 2016-03-29
US20120071413A1
Human necessities

Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)

 #12 | 2011-11-10 ✅ Patent 9,169,325 granted on 2015-10-27
US20110274685A1
Chemistry; metallurgy

Antibodies that bind human CD27 and uses thereof

 #13 | 2011-03-03
US20110053863A1
Human necessities

METHODS OF USING FLT3-LIGAND IN THE TREATMENT OF CANCER

 #14 | 2010-12-02 ✅ Patent 8,318,165 granted on 2012-11-27
US20100303816A1
Chemistry; metallurgy

Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (MCSP)

 #15 | 2010-05-27 ✅ Patent 8,664,176 granted on 2014-03-04
US20100130413A1
Human necessities

Treatment for age-related macular degeneration and other diseases of the eye

 #16 | 2010-05-27 ✅ Patent 8,287,855 granted on 2012-10-16
US20100129396A1
Human necessities

hyperexpressing recombinant cholera toxin B subunit showing dual immunogenicity

 #17 | 2010-04-22 ✅ Patent 8,362,214 granted on 2013-01-29
US20100098704A1
Chemistry; metallurgy

Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)

 #18 | 2009-07-09 ✅ Patent 8,236,318 granted on 2012-08-07
US20090175880A1
Chemistry; metallurgy

Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)

 #19 | 2005-08-18 ✅ Patent 9,259,459 granted on 2016-02-16
US20050180983A1
Chemistry; metallurgy

Antibody vaccine conjugates and uses therefor

Also check out Celldex Therapeutics Inc.'s (Needham, United States) applicant profile with 4 patent applications submitted.

AssigneeID:

8208 ⎘